Legend Biotech (LEGN) EBITDA (2019 - 2025)

Legend Biotech has reported EBITDA for 7 years, with the latest figure at -$19.7 million in Q4 2025.

• For the quarter ending Q4 2025, EBITDA rose 75.16% year-over-year to -$19.7 million; the trailing twelve-month figure through Dec 2025 stood at -$18.1 million (up 80.89% YoY), and the FY2025 full-year result was -$136.5 million, up 55.9% from the prior year.
• EBITDA for Q4 2025 stood at -$19.7 million, down from $40.6 million in the prior quarter.
• The five-year high for EBITDA was $79.5 billion in Q4 2023, with the low at -$206.1 million in Q2 2023.
• Historically, EBITDA has averaged $3.9 billion across 5 years, with a median of -$58.4 million in 2021.
• Annual changes were most pronounced in 2021 — EBITDA slumped 254.08% — and 2023, when it soared 72638.02%.
• Legend Biotech's EBITDA stood at $89.8 million in 2021, then gained by 21.62% to $109.2 million in 2022, then soared by 72638.02% to $79.5 billion in 2023, then slumped by 100.1% to -$79.3 million in 2024, then soared by 75.16% to -$19.7 million in 2025.
• The last three EBITDA figures came in at -$19.7 million (Q4 2025), $40.6 million (Q3 2025), and $1.2 million (Q2 2025), per Business Quant data.